Sector ratings Vanda Pharmaceuticals Inc.

Equities

Market Closed - Nasdaq Other stock markets 21:00:00 19/09/2024 BST			5-day change	1st Jan Change
4.650 ^USD	-6.06%		-6.81%	+10.19%

09-19	Vanda Pharma Shares Fall 15% as FDA Denies Approval of Tradipitant NDA for Treating Gastroparesis Symptoms	MT
09-19	U.S. FDA declines to approve Vanda's stomach paralysis drug	RE

Add to a list Add to a list 0 selected To use this feature you must be a member Log in Sign up	Composite Valuation	ESG Refinitiv	Capi. ($)
VANDA PHARMACEUTICALS INC.	-	C-	271M
VERTEX PHARMACEUTICALS INCORPORATED		B+	123B
REGENERON PHARMACEUTICALS, INC.		B+	124B
ARGENX SE	-	B	32.12B
BIONTECH SE	-	B+	26.75B
BEIGENE, LTD.	-	B	21.11B
GENMAB A/S		A-	16.74B
WUXI APPTEC CO., LTD.		A-	16.4B
INSMED INCORPORATED	-	C	12.88B
NEUROCRINE BIOSCIENCES, INC.		C+	12.16B
SAREPTA THERAPEUTICS, INC.		C+	12.12B
ZEALAND PHARMA A/S	-	B	9.73B
LEGEND BIOTECH CORPORATION	-	D	9.31B
ASCENDIS PHARMA A/S	-	C+	8.8B
AKESO, INC.	-	B-	7.1B
EXELIXIS, INC.		B	7.65B
HALOZYME THERAPEUTICS, INC.		A-	7.54B
Average		B-	26.36B
Weighted average by Cap.		B-